Use of GLP-1 or analogs in treatment of myocardial infarction
AssigneeEli Lilly and Company
InventorSuad Efendic
Life of this patent
Estimating the term…
Abstract
This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.
Claims11
A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a pharmaceutical composition comprising a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives at a dose effective to normalize blood glucose.
A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a compound selected from the group consisting of GLP-1, GLP-1 analogs, and GLP-1 derivatives, wherein the administration occurs within the first 72 hours following a myocardial infarction.
A method of reducing the mortality and morbidity after myocardial infarction, comprising administering to a patient in need thereof, a GLP-1 derivative at a dose effective to normalize blood glucose.
Dependencies are inferred from the claim text.